The Effect of a 13-Valent Conjugate Pneumococcal Vaccine on Circulating Antibodies Against Oxidized LDL and Phosphorylcholine in Man, A Randomized Placebo-Controlled Clinical Trial
In mice vaccination with <i>Streptococcus pneumoniae</i> results in an increase in anti-oxLDL IgM antibodies due to mimicry of anti-phosphorylcholine (present in the cell wall of <i>S. pneumoniae</i>) and anti-oxLDL IgM. In this study we investigated the human translation of...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-10-01
|
| Series: | Biology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-7737/9/11/345 |
| _version_ | 1827703782481330176 |
|---|---|
| author | Hendrika W. Grievink Pim Gal Maria Ozsvar Kozma Erica S. Klaassen Johan Kuiper Jacobus Burggraaf Christoph J. Binder Matthijs Moerland |
| author_facet | Hendrika W. Grievink Pim Gal Maria Ozsvar Kozma Erica S. Klaassen Johan Kuiper Jacobus Burggraaf Christoph J. Binder Matthijs Moerland |
| author_sort | Hendrika W. Grievink |
| collection | DOAJ |
| description | In mice vaccination with <i>Streptococcus pneumoniae</i> results in an increase in anti-oxLDL IgM antibodies due to mimicry of anti-phosphorylcholine (present in the cell wall of <i>S. pneumoniae</i>) and anti-oxLDL IgM. In this study we investigated the human translation of this molecular mimicry by vaccination against <i>S. pneumoniae</i> using the Prevenar-13 vaccine. Twenty-four healthy male volunteers were vaccinated with Prevenar-13, either three times, twice or once in a double-blind, placebo-controlled, randomized single center clinical study. Anti-pneumococcal wall, oxLDL and phosphorycholine antibody levels were measured at a fixed serum dilution, as well as circulating lipid levels over the course of 68 weeks. A significant increase in anti-oxLDL IgG and IgM was seen in the group receiving two doses six months apart compared to the placebo. However, these differences were not observed in the groups receiving a single dose, two doses one month apart, or three doses. This study shows that vaccination with Prevenar-13 does not result in robust anti-oxLDL IgM levels in humans. Further research would be required to test alternative pneumococcal-based vaccines, vaccination regimens or study populations, such as cardiovascular disease patients. |
| first_indexed | 2024-03-10T15:25:45Z |
| format | Article |
| id | doaj.art-8a082be18640447688a99ef3334375e6 |
| institution | Directory Open Access Journal |
| issn | 2079-7737 |
| language | English |
| last_indexed | 2024-03-10T15:25:45Z |
| publishDate | 2020-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biology |
| spelling | doaj.art-8a082be18640447688a99ef3334375e62023-11-20T18:03:31ZengMDPI AGBiology2079-77372020-10-0191134510.3390/biology9110345The Effect of a 13-Valent Conjugate Pneumococcal Vaccine on Circulating Antibodies Against Oxidized LDL and Phosphorylcholine in Man, A Randomized Placebo-Controlled Clinical TrialHendrika W. Grievink0Pim Gal1Maria Ozsvar Kozma2Erica S. Klaassen3Johan Kuiper4Jacobus Burggraaf5Christoph J. Binder6Matthijs Moerland7Centre for Human Drug Research, Zernikedreef 8, 2333 CL Leiden, The NetherlandsCentre for Human Drug Research, Zernikedreef 8, 2333 CL Leiden, The NetherlandsDepartment of Laboratory Medicine, Medical University of Vienna, 1090 Vienna, AustriaCentre for Human Drug Research, Zernikedreef 8, 2333 CL Leiden, The NetherlandsDivision of BioTherapeutics, Leiden Academic Center for Drug Research, Leiden University, Einsteinweg 55, 2333 CC Leiden, The NetherlandsCentre for Human Drug Research, Zernikedreef 8, 2333 CL Leiden, The NetherlandsDepartment of Laboratory Medicine, Medical University of Vienna, 1090 Vienna, AustriaCentre for Human Drug Research, Zernikedreef 8, 2333 CL Leiden, The NetherlandsIn mice vaccination with <i>Streptococcus pneumoniae</i> results in an increase in anti-oxLDL IgM antibodies due to mimicry of anti-phosphorylcholine (present in the cell wall of <i>S. pneumoniae</i>) and anti-oxLDL IgM. In this study we investigated the human translation of this molecular mimicry by vaccination against <i>S. pneumoniae</i> using the Prevenar-13 vaccine. Twenty-four healthy male volunteers were vaccinated with Prevenar-13, either three times, twice or once in a double-blind, placebo-controlled, randomized single center clinical study. Anti-pneumococcal wall, oxLDL and phosphorycholine antibody levels were measured at a fixed serum dilution, as well as circulating lipid levels over the course of 68 weeks. A significant increase in anti-oxLDL IgG and IgM was seen in the group receiving two doses six months apart compared to the placebo. However, these differences were not observed in the groups receiving a single dose, two doses one month apart, or three doses. This study shows that vaccination with Prevenar-13 does not result in robust anti-oxLDL IgM levels in humans. Further research would be required to test alternative pneumococcal-based vaccines, vaccination regimens or study populations, such as cardiovascular disease patients.https://www.mdpi.com/2079-7737/9/11/345cardiovascular diseasevaccineclinical trialstranslational medicineatherosclerosisoxLDL |
| spellingShingle | Hendrika W. Grievink Pim Gal Maria Ozsvar Kozma Erica S. Klaassen Johan Kuiper Jacobus Burggraaf Christoph J. Binder Matthijs Moerland The Effect of a 13-Valent Conjugate Pneumococcal Vaccine on Circulating Antibodies Against Oxidized LDL and Phosphorylcholine in Man, A Randomized Placebo-Controlled Clinical Trial Biology cardiovascular disease vaccine clinical trials translational medicine atherosclerosis oxLDL |
| title | The Effect of a 13-Valent Conjugate Pneumococcal Vaccine on Circulating Antibodies Against Oxidized LDL and Phosphorylcholine in Man, A Randomized Placebo-Controlled Clinical Trial |
| title_full | The Effect of a 13-Valent Conjugate Pneumococcal Vaccine on Circulating Antibodies Against Oxidized LDL and Phosphorylcholine in Man, A Randomized Placebo-Controlled Clinical Trial |
| title_fullStr | The Effect of a 13-Valent Conjugate Pneumococcal Vaccine on Circulating Antibodies Against Oxidized LDL and Phosphorylcholine in Man, A Randomized Placebo-Controlled Clinical Trial |
| title_full_unstemmed | The Effect of a 13-Valent Conjugate Pneumococcal Vaccine on Circulating Antibodies Against Oxidized LDL and Phosphorylcholine in Man, A Randomized Placebo-Controlled Clinical Trial |
| title_short | The Effect of a 13-Valent Conjugate Pneumococcal Vaccine on Circulating Antibodies Against Oxidized LDL and Phosphorylcholine in Man, A Randomized Placebo-Controlled Clinical Trial |
| title_sort | effect of a 13 valent conjugate pneumococcal vaccine on circulating antibodies against oxidized ldl and phosphorylcholine in man a randomized placebo controlled clinical trial |
| topic | cardiovascular disease vaccine clinical trials translational medicine atherosclerosis oxLDL |
| url | https://www.mdpi.com/2079-7737/9/11/345 |
| work_keys_str_mv | AT hendrikawgrievink theeffectofa13valentconjugatepneumococcalvaccineoncirculatingantibodiesagainstoxidizedldlandphosphorylcholineinmanarandomizedplacebocontrolledclinicaltrial AT pimgal theeffectofa13valentconjugatepneumococcalvaccineoncirculatingantibodiesagainstoxidizedldlandphosphorylcholineinmanarandomizedplacebocontrolledclinicaltrial AT mariaozsvarkozma theeffectofa13valentconjugatepneumococcalvaccineoncirculatingantibodiesagainstoxidizedldlandphosphorylcholineinmanarandomizedplacebocontrolledclinicaltrial AT ericasklaassen theeffectofa13valentconjugatepneumococcalvaccineoncirculatingantibodiesagainstoxidizedldlandphosphorylcholineinmanarandomizedplacebocontrolledclinicaltrial AT johankuiper theeffectofa13valentconjugatepneumococcalvaccineoncirculatingantibodiesagainstoxidizedldlandphosphorylcholineinmanarandomizedplacebocontrolledclinicaltrial AT jacobusburggraaf theeffectofa13valentconjugatepneumococcalvaccineoncirculatingantibodiesagainstoxidizedldlandphosphorylcholineinmanarandomizedplacebocontrolledclinicaltrial AT christophjbinder theeffectofa13valentconjugatepneumococcalvaccineoncirculatingantibodiesagainstoxidizedldlandphosphorylcholineinmanarandomizedplacebocontrolledclinicaltrial AT matthijsmoerland theeffectofa13valentconjugatepneumococcalvaccineoncirculatingantibodiesagainstoxidizedldlandphosphorylcholineinmanarandomizedplacebocontrolledclinicaltrial AT hendrikawgrievink effectofa13valentconjugatepneumococcalvaccineoncirculatingantibodiesagainstoxidizedldlandphosphorylcholineinmanarandomizedplacebocontrolledclinicaltrial AT pimgal effectofa13valentconjugatepneumococcalvaccineoncirculatingantibodiesagainstoxidizedldlandphosphorylcholineinmanarandomizedplacebocontrolledclinicaltrial AT mariaozsvarkozma effectofa13valentconjugatepneumococcalvaccineoncirculatingantibodiesagainstoxidizedldlandphosphorylcholineinmanarandomizedplacebocontrolledclinicaltrial AT ericasklaassen effectofa13valentconjugatepneumococcalvaccineoncirculatingantibodiesagainstoxidizedldlandphosphorylcholineinmanarandomizedplacebocontrolledclinicaltrial AT johankuiper effectofa13valentconjugatepneumococcalvaccineoncirculatingantibodiesagainstoxidizedldlandphosphorylcholineinmanarandomizedplacebocontrolledclinicaltrial AT jacobusburggraaf effectofa13valentconjugatepneumococcalvaccineoncirculatingantibodiesagainstoxidizedldlandphosphorylcholineinmanarandomizedplacebocontrolledclinicaltrial AT christophjbinder effectofa13valentconjugatepneumococcalvaccineoncirculatingantibodiesagainstoxidizedldlandphosphorylcholineinmanarandomizedplacebocontrolledclinicaltrial AT matthijsmoerland effectofa13valentconjugatepneumococcalvaccineoncirculatingantibodiesagainstoxidizedldlandphosphorylcholineinmanarandomizedplacebocontrolledclinicaltrial |